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Background
Upper airway diseases (e.g. allergic rhinitis (AR)) are one
of most common causes of chronic cough in subjects with
negative X-ray finding. In UACS (upper airway cough syn-
drome), cough is strongly associated with the ongoing
nasal inflammation. Effective treatment of nasal inflamma-
tion may lead to down regulation of pathologically
enhanced chronic cough. Histamine plays a critical role in
upper airway diseases. All known histamine receptors
(H1R, H2R, H3R, and H4R) have been demonstrated in
the nasal mucosa. Old generation of antihistamines
(inverse agonists of H1R) are empirically used in treatment
of UACS, although their clinical use is limited by their ser-
ious adverse effects. The aim of our study was to ascertain
the effect of H3R selective agonist imetit - known to sup-
press release of substance P from afferent nerves in allergic
nasal inflammation on cough and symptoms of AR in an
animal model.
Method
Guinea pigs (n=10) were sensitised by i.p. administration
of ovalbumin (OVA). Sensitisation was confirmed 21 days
later by skin prick tests. Animals were repeatedly chal-
lenged with i.n. OVA to induce AR and enhanced cough
reflex. When the reliability of the model was confirmed,
animals were pretreated by i.p. administration of imetit
dihydrobromide (1mg/kg and 2mg/kg of body weight)
30 min. prior i.n. OVA administration. AR was evaluated
from the occurrence of typical clinical symptoms including
sneezing, conjunctival and nasal secretion, or nasal acous-
tic phenomenon. The effect on cough was assessed from
the response to inhalation of citric acid (0.4M, 10 min) in
double chamber plethysmograph. Final cough count and
cough latency were analysed from the airflow traces, pre-
sence of cough motor pattern and the cough sound
analysis.
Results
AR up-regulated the cough response from 9±2 to 16±1
cough per provocation, med±IQR, p<0.05 and shortened
cough latency. Imetit (1mg/kg) suppressed nasal symp-
toms and decreased number of cough from 16±1 to
12±1, however the data did not reach significance. Imetit
(2mg/kg) significantly suppressed the nasal symptoms,
and number of coughs from 16±1 to 6±2, med±IQR,
p<0.05. Imetit in both doses did not significantly influ-
ence cough latency.
Conclusion
Imetit in both doses reduces the symptoms of AR,
however only the dose 2mg/kg reduces significantly
total cough count. Cough latency was not significantly
influenced by imetit.
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